J&J CEO Joaquin Duato Files to Sell $12.4M in Stock
JNJ sits 52% above its 52-week low of $169.65.
Summary
J&J CEO Joaquin Duato plans to sell 48,480 shares worth ~$12.4 million, acquired as compensation in February 2026. The sale is small relative to the company's size and follows a pattern of routine insider transactions.
Key Events · Ownership and Investor Activity · JNJ
-
CEO Files to Sell $12.4M in Stock
Joaquin Duato, CEO and Chairman, filed a Form 144 to sell 48,480 shares with an approximate market value of $12,359,006.
-
Shares Acquired as Compensation
The shares were acquired in February 2026 as executive compensation: 4,625 shares on 2/15/2026 and 43,855 shares on 2/13/2026.
-
Minimal Dilution Impact
The proposed sale represents less than 0.002% of J&J's 2.41 billion outstanding shares, making it immaterial to the stock's float.
-
Part of Ongoing Insider Selling Pattern
This is the third Form 144 filing by J&J insiders in the past 90 days, indicating routine portfolio diversification rather than a negative signal.
Analysis · JNJ · Life Sciences
CEO Joaquin Duato filed a Form 144 to sell 48,480 shares worth approximately $12.4 million. While the dollar amount is significant, it represents a tiny fraction of J&J's $621 billion market cap and less than 0.002% of outstanding shares. The sale is part of a pattern of periodic insider selling, and the shares were acquired as executive compensation earlier this year. Given Duato's dual role as CEO and Chairman, the filing draws attention, but the size relative to the company is modest and unlikely to move the stock.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 28.9% of the 1476 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JNJ was trading at $258.24 on NYSE in the Life Sciences sector, with a market capitalization of approximately $620.8B. The 52-week trading range was $169.65 to $274.90. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.